Product Code: GDHCER085-15
Growth hormone deficiency (GHD) is an endocrine disorder characterized by low or deficient secretion of growth hormone (GH) secondary to malfunction of the pituitary gland, a pea-sized structure located at the base of the brain that is responsible for the production of GH. The International Classification of Diseases (ICD-10) ICD-10-CM code for GHD is E23.0.
GHD in children can be classified as idiopathic or organic, which is further divided into congenital and acquired. GH is necessary for normal growth, as it fuels childhood growth and development. In an adult's normal lifespan, GH is needed to maintain the amounts of body fat, muscle, and bone necessary for sustaining tissue and organ function. GHD acquired in adulthood is usually acquired through damage to the pituitary-hypothalamic region through trauma or tumors. This report does not cover childhood-onset GHD that progresses into adulthood.
In the 7MM, the diagnosed prevalent cases of GHD for all ages and both sexes will increase from 97,985 cases in 2014 to 100,494 cases in 2024, at an Annual Growth Rate (AGR) of 0.26%. GlobalData epidemiologists forecast a small increase in the AGR of the diagnosed prevalent cases of GHD from 2014-2024 for all included markets except for Germany and Japan. The majority of diagnosed prevalent cases of GHD in children in the 7MM are in boys. In the 7MM, 68.05% of the GHD cases in children are in boys and the trend is consistent in the individual markets. In adults, the distribution is also skewed towards men in the US and the 5EU.
GlobalData epidemiologists maintained consistent forecast methodology across all the 7MM, thus allowing for a meaningful comparison of the included parameters across the 7MM.
- The Growth Hormone Deficiency (GHD) EpiCast Report provides an overview of the risk factors and global trends of GHD in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the GHD diagnosed in children (=18 years) and in adults (>18 years) segmented by sex from 2014-2024. The forecast also provides GHD diagnosed cases in children segmented by the etiological classifications (idiopathic and organic; organic further segmented into congenital and acquired). The forecast for GHD diagnosed in adults are further segmented by etiological classifications (idiopathic and acquired).
- The GHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global GHD market.
- Quantify patient populations in the global GHD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for GHD therapeutics in each of the markets covered.
- Identify the percentage of GHD diagnosed prevalent cases by etiological classification.
Table of Contents
1. Table of Contents
- 1.1. List of Tables
- 1.2. List of Figures
- 2.1. Catalyst
- 2.2. Related Reports
- 2.3. Upcoming Reports
- 3.1. Disease Background
- 3.1.1. GHD in Children
- 3.1.2. GHD in Adults
- 3.2. Risk Factors and Comorbidities
- 3.3. Global Trends
- 3.3.1. GHD in Children
- 3.3.2. GHD in Adults
- 3.4. Forecast Methodology
- 3.4.1. Sources Used
- 3.4.2. Sources Not Used
- 3.4.3. Forecast Assumptions and Methods
- 3.5. Epidemiological Forecast of GHD (2014-2024)
- 3.5.1. Diagnosed Prevalent Cases of GHD
- 3.5.2. Diagnosed Prevalent Cases of GHD by Sex
- 3.5.3. Diagnosed Prevalent Cases of GHD by Age
- 3.5.4. Age-Adjusted Diagnosed Prevalence of GHD
- 3.5.5. Diagnosed Prevalent Cases of GHD in Children by Etiological Classification
- 3.5.6. Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification
- 3.6. Discussion
- 3.6.1. Epidemiological Forecast Insight
- 3.6.2. Limitations of the Analysis
- 3.6.3. Strengths of the Analysis
- 4.1. Bibliography
- 4.2. About the Authors
- 4.2.1. Epidemiologists
- 4.2.2. Reviewers
- 4.2.3. Global Director of Therapy Analysis and Epidemiology
- 4.2.4. Global Head of Healthcare
- 4.3. About GlobalData
- 4.4. About EpiCast
- 4.5. Disclaimer
List of Tables
- Table 1: Risk Factors for GHD
- Table 2: 7MM, Sources for the Diagnosed Cases of GHD in Children
- Table 3: 7MM, Sources for the Prevalent Cases of GHD Diagnosed in Adults
- Table 4: 7MM, Sources for the Etiological Classifications of Diagnosed Prevalent Cases of GHD in Children
- Table 5: 7MM, Sources for the Etiological Classifications of Diagnosed Prevalent Cases of GHD in Adults
- Table 6: 7MM, Diagnosed Prevalent Cases of GHD, All Ages, Both Sexes, N, Selected Years 2014-2024
- Table 7: 7MM, Diagnosed Prevalent Cases of GHD by Sex, Children and Adults, N (Row %), 2014
- Table 8: 7MM, Diagnosed Prevalent Cases of GHD in Children, Both Sexes, Ages ≥18 Years, N, Selected Years 2014-2024
- Table 9: 7MM, Diagnosed Prevalent Cases of GHD in Adults, Both Sexes, Ages >18 Years, N, Selected Years 2014-2024
- Table 10: 7MM, Diagnosed Prevalent Cases of GHD by Etiological Classification, N (Col %), Both Sexes, Ages ≥18, 2014
- Table 11: 7MM, Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification, N (Row %), Both Sexes, Ages >18, 2014
List of Figures
- Figure 1: 7MM, Diagnosed Prevalence of GHD in Children, Both Sexes, Ages ≥18 Years
- Figure 2: 7MM, Diagnosed Prevalence of GHD in Adults, Both Sexes, Ages >18 Years
- Figure 3: Case-Flow for GHD Epidemiological Forecast
- Figure 4: 7MM, Diagnosed Prevalent Cases of GHD, Both Sexes, All Ages, N, 2014-2024
- Figure 5: 7MM, Age-Specific Diagnosed Prevalent Cases of GHD, Both Sexes, Ages ≥18 Years, 2014
- Figure 6: 7MM, Age-Specific Diagnosed Prevalent Cases of GHD, Both Sexes, Ages >18 Years, 2014
- Figure 7: 7MM, Age-Standardized Diagnosed Prevalence of GHD, All Ages, by Sex, 2014